HERMOD Project Launched to Explore Parkinson’s Treatment
A new European initiative aims to assess HER-096, a potential therapy for recently diagnosed Parkinson’s patients.
The HERMOD project, funded by Horizon Europe, aims to study HER-096's effects on Parkinson's disease.
The phase II trial will involve around 100 participants across Europe, focusing on safety and efficacy.
Parkinson's disease caused approximately 93,000 deaths in Europe in 2023, underscoring the need for effective treatments.
On November 11, Herantis Pharma announced the launch of the HERMOD project, a European collaboration aimed at developing an investigational treatment for Parkinson’s disease, specifically targeting individuals who have recently been diagnosed. This initiative is funded through Horizon Europe and brings together clinical, academic, and industry partners to conduct a phase II study of the drug HER-096.
HER-096 is being investigated as a potential disease-modifying therapy, with researchers exploring its ability to influence the underlying mechanisms of Parkinson’s disease. The treatment is based on cerebral dopamine neurotrophic factor, a protein known for its protective role in nerve cells. It is engineered to penetrate the blood-brain barrier and address cellular stress pathways associated with the disease.
The project aims to integrate clinical assessments with digital monitoring and imaging techniques to gather comprehensive evidence regarding the treatment's effects. While it remains to be determined whether HER-096 can effectively slow disease progression, preliminary findings from a phase Ib trial indicated that the treatment was generally safe and well tolerated among participants.
The upcoming phase II study plans to enroll approximately 100 participants from various European clinical sites. This trial will consist of a 36-week randomized, double-blind, placebo-controlled phase, followed by a 24-week period where all participants will receive the active treatment. Researchers will evaluate the treatment's efficacy, safety, and tolerability, while also investigating digital biomarkers that may indicate treatment effects and changes in disease progression.
Parkinson’s disease is a significant health concern, having resulted in an estimated 93,000 deaths across Europe in 2023, according to data from the Global Burden of Disease. This collaboration, which includes partners from Sweden, Finland, and Luxembourg, seeks to address the urgent need for effective treatments. The European Commission has allocated approximately €8 million for the HERMOD project, which is set to continue until May 2030, with the goal of enhancing the measurement of motor function changes and exploring biomarkers related to disease progression.




